Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

Source: Getty Images Clinicians should have a standard approach for discussing the risk of adverse events associated with immune checkpoint inhibitors, researchers say. The most common immune-related ...

Checkpoint inhibitors are a novel breakthrough that unleash the immune system’s natural cancer-fighting abilities—mainly surveilling the body and eliminating any cancer cells it finds.

Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but many patients with metastatic cancer develop resistance. Understanding the mechanisms behind this resistance is ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

Cytokine analysis in cancer patients reveals biomarkers for predicting immune-related adverse reactions, aiding in the ...

No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib ...

Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments. Researchers conducted a ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with ...